Continued Funding of ProNoxis
Continued confidence and investments in Redoxis associated company ProNoxis AB
With operations proceeding as planned, ProNoxis AB has secured SEK 4,0 million in a new round of financing. Signaling confidence in ProNoxis development to date, lead investor LU Bioscience has invested SEK 2,0 million and Karolinska Development SEK 2,0 million. The investment will give proof of principal in an arthritis model from lead candidates and continued lead development. LU Bio and Karolinska Development now hold 32 % and 22 % of ProNoxis, respectively. Redoxis AB holds the remaining 46 %.